{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:41:54Z","timestamp":1768923714198,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NCI","award":["5P30CA124435"],"award-info":[{"award-number":["5P30CA124435"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"NCRR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cllc.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T22:06:22Z","timestamp":1540245982000},"page":"e208-e217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non\u2013small-cell Lung Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Nathaniel J.","family":"Myall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1591-1897","authenticated-orcid":false,"given":"Solomon","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-9696","authenticated-orcid":false,"given":"Douglas","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summer S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.10.003_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.10.003_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.10.003_bib3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.10.003_bib4","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2018.10.003_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.cllc.2018.10.003_bib6","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper","year":"2013","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2018.10.003_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2018.10.003_bib8","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib9","first-page":"4619","article-title":"Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer","volume":"31","author":"Kobayashi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2018.10.003_bib10","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.10.003_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/annonc\/mdt495","article-title":"Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations","volume":"25","author":"Kinno","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/cncr.30463","article-title":"Clinicopathological features and clinical outcomes associated with TP53 and BRAF-non-V600 mutations in cutaneous melanoma patients","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib13","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cncr.29042","article-title":"Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium","volume":"121","author":"Villaruz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","article-title":"Clinical characteristics and course of 63 patients with BRAF mutant lung cancer","volume":"9","author":"Litvak","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2015.11.006","article-title":"Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations","volume":"91","author":"Tissot","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicenter, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutated metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2018.10.003_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.10.003_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cancergen.2015.04.001","article-title":"BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer","volume":"208","author":"Goldman","year":"2015","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cllc.2018.10.003_bib23","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.cllc.2015.12.001","article-title":"Long-term survival of a patient with non-small-cell lung cancer harboring a V600E mutation in the BRAF oncogene","volume":"17","author":"Myall","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib24","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/djs353","article-title":"When progressive disease does not mean treatment failure: reconsidering the criteria for progression","volume":"104","author":"Oxnard","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2018.10.003_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/PAS.0b013e31816597ca","article-title":"The histopathology of BRAF-V600E-mutated lung adenocarcinoma","volume":"32","author":"Yousem","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2018.10.003_bib26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/cncr.24871","article-title":"Five-year lung cancer survival: which advanced stage non-small cell lung cancer patients attain long-term survival?","volume":"116","author":"Wang","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1440-1843.2011.02070.x","article-title":"Factors associated with long-term survival of patients with advanced non-small cell lung cancer","volume":"17","author":"Giroux Leprieur","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.cllc.2018.10.003_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/cncr.29313","article-title":"Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas","volume":"121","author":"Yu","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12022-009-9101-3","article-title":"Absence of BRAF, NRSA, KRAS, HRAS mutations, and RET\/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas","volume":"21","author":"Sadow","year":"2010","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.cllc.2018.10.003_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/thy.2013.0403","article-title":"Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations","volume":"24","author":"Barollo","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.cllc.2018.10.003_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2014.01.023","article-title":"BRAF-mutations in non-small cell lung cancer","volume":"84","author":"Brustugun","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.10.003_bib32","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.cllc.2018.10.003_bib33","first-page":"v460","article-title":"Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: results of the Network Genomic Medicine","volume":"28","author":"Kron","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.10.003_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00107","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830264X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830264X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:49Z","timestamp":1761505729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041830264X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S152573041830264X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.10.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non\u2013small-cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}